Review
Medicine, General & Internal
Davide Lazzarotto, Anna Candoni
Summary: Monitoring Minimal Residual Disease (MRD) is crucial in acute myeloid leukemia (AML) for guiding treatment, determining the need for stem cell transplantation, and detecting relapse early. However, more than 50% of AML patients lack specific molecular markers for MRD monitoring. This review focuses on the use of WT1 overexpression as an MRD marker in AML patients undergoing intensive chemotherapy, including stem cell transplantation. The standardized method of European LeukemiaNet is recommended for achieving optimal sensitivity and specificity.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Oncology
Michele Malagola, Nicola Polverelli, Alessandra Beghin, Federica Bolda, Marta Comini, Mirko Farina, Enrico Morello, Vera Radici, Eugenia Accorsi Buttini, Simona Bernardi, Federica Re, Alessandro Leoni, Davide Bonometti, Duilio Brugnoni, Arnalda Lanfranchi, Domenico Russo
Summary: We retrospectively analyzed the impact of bone marrow CD34+ molecular chimerism and WT1 on the outcome of AML patients submitted to allogeneic stem cell transplantation. The cumulative incidence of relapse was significantly lower in patients with high donor chimerism on CD34+ cells and low WT1 levels at 1st and 3rd month post-transplantation. By combining chimerism and WT1 at 3rd month, patients with intermediate prognosis could be identified.
FRONTIERS IN ONCOLOGY
(2023)
Article
Medical Laboratory Technology
Linnea Pettersson, Francesco Vezzi, Sofie Vonlanthen, Karin Alwegren, Anders Hedrum, Dan Hauzenberger
Summary: This study aimed to evaluate a novel NGS-based assay for monitoring mixed chimerism, and found that NGS demonstrated high sensitivity and good accuracy, outperforming real-time PCR and fragment analysis techniques.
CLINICA CHIMICA ACTA
(2021)
Review
Oncology
Charalampos Charalampous, Taxiarchis Kourelis
Summary: Multiple Myeloma (MM) is a common hematologic malignancy with significant therapeutic advances in recent years; however, a curative treatment option is still lacking. Accurate detection of Minimal Residual Disease (MRD) from a bone marrow biopsy plays a crucial role in evaluating treatment response. As patients' life expectancy increases and deep responses become more common, studying and refining the role of MRD in the disease course becomes increasingly important.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Natasha Honore, Rachel Galot, Cedric van Marcke, Nisha Limaye, Jean-Pascal Machiels
Summary: Liquid biopsy is rapidly evolving as a tool for detecting minimal residual disease in cancer patients, but it still faces technical challenges and limitations that need to be addressed for its clinical applicability.
Article
Oncology
Rafael Colmenares, Noemi alvarez, Santiago Barrio, Joaquin Martinez-Lopez, Rosa Ayala
Summary: The study of cell-free DNA and other peripheral blood components shows great promise in the field of hematological malignancies, particularly in the diagnosis, prognosis, and treatment response. However, there are still limitations and further research and standardization are needed.
Review
Oncology
Carlos Bravo-Perez, Maria Sola, Raul Teruel-Montoya, Maria Dolores Garcia-Malo, Francisco Jose Ortuno, Vicente Vicente, Felipe de Arriba, Andres Jerez
Summary: The response rates in multiple myeloma have increased significantly, leading to a focus on measuring minimal residual disease (MRD) in order to assess and treat patients. The use of novel agents has created a paradigm shift in MM treatment, raising questions about standard measures, high sensitivity methods, and the relevance of current response criteria. Lessons learned from other neoplasms and efforts to harmonize methods for measuring MRD in MM are discussed in this review.
Review
Oncology
Hong Ding, Juan Xu, Zhimei Lin, Jingcao Huang, Fangfang Wang, Yan Yang, Yushan Cui, Hongmei Luo, Yuhan Gao, Xinyu Zhai, Weicui Pang, Li Zhang, Yuhuan Zheng
Summary: MRD in MM plays a critical role in disease pathogenesis, demonstrating unique cytogenetic aberrations and gene expression profiles. Different risk MM exhibit diverse MRD features, with clonal evaluation potentially occurring at the MRD stage. MM MRD before and after treatment shows distinct differences.
BIOMARKER RESEARCH
(2021)
Article
Oncology
Patrizia Chiusolo, Elisabetta Metafuni, Gessica Minnella, Sabrina Giammarco, Silvia Bellesi, Monica Rossi, Federica Sora, Maria Assunta Limongiello, Filippo Frioni, Nicola Piccirillo, Maria Bianchi, Caterina Giovanna Valentini, Luciana Teofili, Simona Sica, Andrea Bacigalupo
Summary: The aim of this study was to evaluate the role of WT1 expression after allogeneic stem cell transplantation (alloHSCT) in patients with acute myeloid leukemia (AML). The results showed that WT1 expression at day 60 is a significant predictor of relapse, particularly when tested on CD34+ selected bone marrow cells.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Noemi Puig, Juan Flores-Montero, Leire Burgos, Maria-Teresa Cedena, Lourdes Cordon, Jose-Juan Perez, Luzalba Sanoja-Flores, Irene Manrique, Paula Rodriguez-Otero, Laura Rosinol, Joaquin Martinez-Lopez, Maria-Victoria Mateos, Juan-Jose Lahuerta, Joan Blade, Jesus F. San Miguel, Alberto Orfao, Bruno Paiva
Summary: Our study supports the routine assessment of bone marrow cellularity to evaluate hemodilution, using treatment-specific or healthy adult reference values to indicate potential false-negative minimal residual disease results.
Review
Oncology
Andrea Nicolini, Giuseppe Rossi, Paola Ferrari, Angelo Carpi
Summary: This article focuses on the research of the mechanisms behind the dissemination and colonization of cancer cells, with the aim of preventing and treating metastatic tumors more effectively. A proposed strategy involves immune modulation and stimulation to downregulate immune escape mechanisms and target dormant cancer cells. Preliminary clinical and laboratory data suggest the efficacy of this strategy in certain types of cancers.
SEMINARS IN CANCER BIOLOGY
(2022)
Article
Immunology
Wenjie Xiong, Zanzan Wang, Tingyu Wang, Ying Yu, Yanshan Huang, Hao Sun, Jiawen Chen, Rui Lyu, Huijun Wang, Yuting Yan, Qi Wang, Wei Liu, Gang An, Weiwei Sui, Wenyang Huang, Dehui Zou, Zhijian Xiao, Jianxiang Wang, Guifang Ouyang, Lugui Qiu, Shuhua Yi
Summary: This study analyzed the prognostic value of minimal residual disease (MRD) in Waldenstrom macroglobulinemia (WM) patients. They found that MRD positivity is an independent prognostic factor for progression-free survival (PFS) and its assessment can improve response evaluation.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Oncology
Maroun Bou Zerdan, Joseph Kassab, Ludovic Saba, Elio Haroun, Morgan Bou Zerdan, Sabine Allam, Lewis Nasr, Walid Macaron, Mahinbanu Mammadli, Sarah Abou Moussa, Chakra P. Chaulagain
Summary: The assessment of minimal residual disease (MRD) using peripheral blood instead of bone marrow aspirate/biopsy or cancerous biopsy is a promising technique that requires further research and technological innovation. In some lymphoid malignancies, monitoring MRD in peripheral blood has shown potential as an alternative to frequent bone marrow aspirations. However, more studies are needed to investigate the biology of liquid biopsies in these malignancies and their feasibility in larger patient cohorts.
FRONTIERS IN ONCOLOGY
(2023)
Article
Biochemical Research Methods
Peter Juelg, Elena Kipf, Mara Specht, Marion Fillies, Cornelia Eckert, Nils Paust, Roland Zengerle, Michael Lehnert, Tobias Hutzenlaub
Summary: This study introduces an automated, highly sensitive, and multiplexed qPCR quantification method using centrifugal microfluidics, showing promising results in clinical applications for disease monitoring. The approach demonstrated high accuracy in generating standard curves, specificity controls, and quantifying patient samples, providing a potential solution for reproducible gene quantification in moderate-throughput settings.
Article
Oncology
Hareth Nahi, Gabriel Afram, Katarina Uttervall, Sandra Lockmer, Love Tatting, Gosta Gahrton, Muhammad Kashif, Evren Alici, Olga Stromberg, Monika Klimkowska, Johan Lund
Summary: Being MRD- is a more crucial prognostic factor for the 3-year PFS and OS than the presence of high-risk cytogenetic markers or undergoing maintenance treatment in multiple myeloma patients.
Article
Hematology
Michelina Dargenio, Massimiliano Bonifacio, Sabina Chiaretti, Antonella Vitale, Nicola Stefano Fracchiolla, Cristina Papayannidis, Fabio Giglio, Prassede Salutari, Ernesta Audisio, Barbara Scappini, Patrizia Zappasodi, Marzia Defina, Fabio Forghieri, Anna Maria Scattolin, Elisabetta Todisco, Monia Lunghi, Fabio Guolo, Maria Ilaria Del Principe, Mario Annunziata, Davide Lazzarotto, Michele Cedrone, Crescenza Pasciolla, Annalisa Imovilli, Ilaria Tanasi, Silvia Trappolini, Marco Cerrano, Roberta La Starza, Mauro Krampera, Nicola Di Renzo, Anna Candoni, Giovanni Pizzolo, Felicetto Ferrara, Robin Foa
Summary: This study analyzed the incidence, characteristics, treatment, and outcome of central nervous system (CNS) relapse in adult acute lymphoblastic leukemia (ALL) patients. The study found that 6.8% of patients experienced a CNS recurrence, with a higher incidence in T-cell ALL than in B-cell ALL. Risk factors for early CNS relapse included T-cell phenotype, hyperleucocytosis, and male gender. Treatment options varied, including chemotherapy, radiotherapy, intrathecal therapy, and novel agents. Allogenic transplant after complete remission showed a significant overall survival benefit. The time to CNS relapse was the strongest predictor of post-relapse survival.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Hematology
Davide Lazzarotto, Ilaria Tanasi, Antonella Vitale, Matteo Piccini, Michelina Dargenio, Fabio Giglio, Fabio Forghieri, Nicola Fracchiolla, Marco Cerrano, Elisabetta Todisco, Cristina Papayannidis, Matteo Leoncin, Marzia Defina, Fabio Guolo, Crescenza Pasciolla, Mario Delia, Patrizia Chiusolo, Antonino Mule, Anna Candoni, Massimiliano Bonifacio, Giovanni Pizzolo, Robin Foa
Summary: Mixed-phenotype acute leukemia (MPAL) is a rare disease, and its treatment is often similar to that of acute lymphoblastic leukemia (ALL). This study found that MPAL patients respond better to an ALL-like induction therapy, and consolidation therapy should include allogeneic stem cell transplantation (AlloSCT) whenever possible. Additionally, achieving minimal residual disease (MRD) negativity should be a primary goal of treatment.
ANNALS OF HEMATOLOGY
(2023)
Article
Oncology
Giovanni Marconi, Anna Candoni, Roberta Di Nicola, Chiara Sartor, Sarah Parisi, Mariachiara Abbenante, Jacopo Nanni, Gianluca Cristiano, Letizia Zannoni, Davide Lazzarotto, Benedetta Giannini, Carmen Baldazzi, Lorenza Bandini, Emanuela Ottaviani, Nicoletta Testoni, Chiara Di Giovanni Bezzi, Rania Abd-alatif, Giulia Ciotti, Renato Fanin, Giovanni Martinelli, Stefania Paolini, Paolo Ricci, Michele Cavo, Cristina Papayannidis, Antonio Curti
Summary: In elderly AML patients, early response and biology-based risk classification can predict survival, but a comprehensive disease model has limitations in stratification. Baseline comorbidity burden may also impact prognosis. Therefore, a comprehensive approach that combines AML biology with tailored interventions to patients' frailty is likely to fully exploit the anti-leukemia potential of novel drugs.
Article
Oncology
Esther Natalie Oliva, Anna Candoni, Prassede Salutari, Giuseppe A. Palumbo, Gianluigi Reda, Giuseppe Ianni, Giovanni Tripepi, Maria Cuzzola, Debora Capelli, Corrado Mammi, Caterina Alati, Maria Concetta Cannata, Pasquale Niscola, Bianca Serio, Pellegrino Musto, Ernesto Vigna, Antonio Volpe, Lorella Maria Antonia Melillo, Maria Teresa Arcadi, Donato Mannina, Maria Elena Zannier, Roberto Latagliata
Summary: Azacitidine (AZA) is a hypomethylating agent used for frontline treatment of acute myeloid leukemia (AML) in patients unfit for intensive chemotherapy. Recent research showed that maintenance therapy with AZA during complete remission improved disease-free survival (DFS) up to 2 and 5 years in AML patients aged >68 years.
Article
Oncology
Marica De Cicco, Ivana Lagreca, Sabrina Basso, Patrizia Barozzi, Stella Muscianisi, Alba Bianco, Giovanni Riva, Sara Di Vincenzo, Chiara Pulvirenti, Davide Sapuppo, Mariangela Siciliano, Vittorio Rosti, Anna Candoni, Marco Zecca, Fabio Forghieri, Mario Luppi, Patrizia Comoli
Summary: This study investigated the feasibility of producing mutated-NPM1-specific cytotoxic T cells (CTLs) for the treatment of NPM1-mutated AML patients. The results showed that mutated-NPM1-specific CTLs with specific cytokine production and high cytotoxicity against patients' leukemia cells could be obtained from both patients and donors. These polyfunctional mutated-NPM1-specific CTLs included both CD8+ and CD4+ T cells with strong lytic capacity.
Letter
Hematology
Gabriele Facchin, Giulia Battaglia, Assunta Sartor, Carla Fili, Maria Elena Zannier, Marta Lisa Battista, Renato Fanin, Anna Candoni
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES
(2023)
Article
Hematology
Renato Bassan, Sabina Chiaretti, Irene Della Starza, Orietta Spinelli, Alessandra Santoro, Francesca Paoloni, Monica Messina, Loredana Elia, Maria Stefania De Propris, Anna Maria Scattolin, Ernesta Audisio, Laura Marbello, Erika Borlenghi, Patrizia Zappasodi, Elisa Mauro, Giovanni Martinelli, Daniele Mattei, Nicola Fracchiolla, Monica Bocchia, Paolo De Fabritiis, Massimiliano Bonifacio, Anna Candoni, Vincenzo Cassibba, Paolo Di Bartolomeo, Giancarlo Latte, Silvia Trappolini, Anna Guarini, Antonella Vitale, Paola Fazi, Alfonso Piciocchi, Alessandro Rambaldi, Robin Foa
Summary: This study demonstrates that pediatric-inspired chemotherapy is the standard of care for younger adults with Philadelphia chromosome-negative acute lymphoblastic leukemia/lymphoma (Ph- ALL/ LL). The addition of pegaspargase improves survival rates, particularly in younger patients and those without residual disease.
Article
Biology
Alberto Magi, Gianluca Mattei, Alessandra Mingrino, Chiara Caprioli, Chiara Ronchini, GianMaria Frige, Roberto Semeraro, Davide Bolognini, Alessandro Rambaldi, Anna Candoni, Emanuela Colombo, Luca Mazzarella, Pier Giuseppe Pelicci
Summary: DNA methylation patterns in sparse CpG regions drive chemoresistance in Acute Myeloid Leukemia patients.
COMMUNICATIONS BIOLOGY
(2023)
Correction
Biology
Alberto Magi, Gianluca Mattei, Alessandra Mingrino, Chiara Caprioli, Chiara Ronchini, Gianmaria Frige, Roberto Semeraro, Davide Bolognini, Alessandro Rambaldi, Anna Candoni, Emanuela Colombo, Luca Mazzarella, Pier Giuseppe Pelicci
COMMUNICATIONS BIOLOGY
(2023)
Article
Medicine, Research & Experimental
Pierantonio Menna, Francesco Marchesi, Chiara Cattaneo, Anna Candoni, Mario Delia, Gianpaolo Nadali, Alessandra Vatteroni, Crescenza Pasciolla, Salvatore Perrone, Luisa Verga, Daniele Armiento, Maria Ilaria Del Principe, Nicola S. S. Fracchiolla, Emanuela Salvatorelli, Santina Lupisella, Irene Terrenato, Alessandro Busca, Giorgio Minotti, Livio Pagano
Summary: Midostaurin is commonly used with chemotherapy for newly diagnosed FLT3-mutated acute myeloid leukemia. However, chemotherapy-induced neutropenia increases the risk of invasive fungal infections. Posaconazole is recommended for antifungal prophylaxis, but its inhibition of CYP3A4 affects the metabolism of midostaurin. A study was conducted to evaluate the interactions between posaconazole and midostaurin and their impact on treatment outcomes. Despite concerns, posaconazole remained the preferred antifungal choice for midostaurin-treated patients.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE
(2023)
Letter
Hematology
Chiara Callegari, Davide Lazzarotto, Alessandra Soravia, Martina Mutti, Pietro Lauzzana, Maddalena Peghin, Stefano Cordella, Renato Fanin, Anna Candoni
EUROPEAN JOURNAL OF HAEMATOLOGY
(2023)
Article
Oncology
Luana Fianchi, Fabio Guolo, Francesco Marchesi, Chiara Cattaneo, Michele Gottardi, Francesco Restuccia, Anna Candoni, Elettra Ortu La Barbera, Rita Fazzi, Crescenza Pasciolla, Olimpia Finizio, Nicola Fracchiolla, Mario Delia, Federica Lessi, Michelina Dargenio, Valentina Bonuomo, Maria Ilaria Del Principe, Patrizia Zappasodi, Marco Picardi, Claudia Basilico, Monica Piedimonte, Paola Minetto, Antonio Giordano, Patrizia Chiusolo, Lucia Prezioso, Caterina Buquicchio, Lorella Maria Antonia Melillo, Daniele Zama, Francesca Farina, Valentina Mancini, Irene Terrenato, Michela Rondoni, Irene Urbino, Mario Tumbarello, Alessandro Busca, Livio Pagano
Summary: This study evaluated the absolute infectious risk in 200 AML patients treated with CPX-351 and found it to have a good safety profile, with an incidence of infectious complications comparable to that of pivotal studies. The only factor significantly associated with mortality was a lack of response to CPX-351 treatment.
Article
Health Care Sciences & Services
Davide Giusti, Elisabetta Colaci, Valeria Pioli, Federico Banchelli, Monica Maccaferri, Giovanna Leonardi, Roberto Marasca, Monica Morselli, Fabio Forghieri, Francesca Bettelli, Angela Cuoghi, Paola Bresciani, Andrea Messerotti, Andrea Gilioli, Anna Candoni, Luca Cassanelli, Elena Sbadili, Ilaria Bassoli, Giuseppe Longo, Fabio Gilioli, Eleonora Borelli, Sarah Bigi, Roberto D'Amico, Carlo Adolfo Porro, Oreofe Odejide, Camilla Zimmermann, Fabio Efficace, Eduardo Bruera, Mario Luppi, Elena Bandieri, Leonardo Potenza
Summary: This study compared the quality indicators for palliative and end of life care in multiple myeloma patients receiving early palliative care (EPC) with those receiving usual haematological care (UHC). The results showed that patients receiving EPC had significantly higher numbers of quality indicators and reduced pain intensity compared to those receiving UHC.
BMJ SUPPORTIVE & PALLIATIVE CARE
(2023)
Correction
Hematology
V Marasco, A. Piciocchi, A. Candoni, L. Pagano, A. Guidetti, P. Musto
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Hematology
Michael Luebbert, Pierre W. Wijermans, Michal Kicinski, Sylvain Chantepie, Walter J. F. M. Van der Velden, Richard Noppeney, Laimonas Griskevicius, Andreas Neubauer, Martina Crysandt, Radovan Vrhovac, Mario Luppi, Stephan Fuhrmann, Ernesta Audisio, Anna Candoni, Olivier Legrand, Robin Foa, Gianluca Gaidano, Danielle van Lammeren-Venema, Eduardus F. M. Posthuma, Mels Hoogendoorn, Anne Giraut, Marian Stevens-Kroef, Joop H. Jansen, Aniek O. de Graaf, Fabio Efficace, Emanuele Ammatuna, Jean-Pierre Vilque, Ralph Waesch, Heiko Becker, Nicole Blijlevens, Ulrich Duehrsen, Frederic Baron, Stefan Suciu, Sergio Amadori, Adriano Venditti, Gerwin Huls
Summary: This study compares the efficacy and safety of decitabine monotherapy with intensive chemotherapy in older patients with acute myeloid leukemia. The results show that 10-day decitabine monotherapy is as effective and safer than 3 + 7 chemotherapy in older patients.
LANCET HAEMATOLOGY
(2023)